PHS
BBIO icon

PFM Health Sciences’s BridgeBio Pharma BBIO Stock Holding History

PFM Health Sciences’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,000
Closed -$1.37M – 69
2024
Q4 		$1.37M Buy
+50,000
New +$1.29M 0.09% 76

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PFM Health Sciences's BBIO Position: Q1 2026 in Review

PFM Health Sciences reduced its BridgeBio Pharma (BBIO) stake by 16% in Q1 2026, selling an estimated $3.53M and leaving 257,747 shares worth $19.1M. The position accounts for 1.75% of the portfolio, ranked #16.

PFM Health Sciences first reported a position in BBIO in Q4 2024 and has held it in 6 quarters since. The position peaked at $31.4M in Q1 2025. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • PFM Health Sciences held 257,747 shares of BridgeBio Pharma worth $19.1M as of Q1 2026.
  • PFM Health Sciences sold 48,759 BridgeBio Pharma shares in Q1 2026, an estimated $3.53M.
  • BridgeBio Pharma made up 1.75% of PFM Health Sciences's portfolio in Q1 2026, its #16 holding.
  • PFM Health Sciences first reported a position in BridgeBio Pharma in Q4 2024 and has held it in 6 quarters since.
  • PFM Health Sciences's BridgeBio Pharma position peaked at $31.4M in Q1 2025.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.